Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses with Systemic Pelareorep Treatment

Recently announced clinical data demonstrate pelareorep-induced priming of an adaptive immune response Pro-inflammatory effects of pelareorep observed across multiple breast cancer subtypes Data support further clinical development of pelareorep-anti-PD-L1 combination therapies San Diego, CA and Calgary, AB — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL)…
Read more